Adilip 135 Tablet

Adilip 135 Tablet contains Fenofibrate 135 mg (as fenofibrate) tablet. Prescription required.

Treatment of dyslipidaemia such as high triglycerides (hypertriglyceridaemia) and mixed dyslipidaemia; used to reduce risk of pancreatitis associated with very high triglycerides; adjunct to diet and lifestyle changes.

Fenofibrate activates PPAR-α, which increases lipolysis and clearance of triglyceride-rich lipoproteins by inducing lipoprotein lipase and reducing apolipoprotein C-III. This lowers triglycerides and VLDL and can raise HDL cholesterol.

Oral tablet. Take as prescribed by the doctor, usually once daily; best taken with or after food to improve absorption. Swallow whole with water; continue diet, exercise and weight control alongside therapy.

Abdominal pain, nausea, diarrhoea, indigestion, headache, raised liver enzymes, back pain, muscle pain

Not for use in severe kidney disease, active liver disease, gallbladder disease, or allergy to fenofibrate/fibric acid derivatives. Risk of muscle toxicity (myopathy/rhabdomyolysis), especially with statins, in elderly, diabetes, hypothyroidism or renal impairment—report unexplained muscle pain/weakness. Periodic monitoring of liver function tests, renal function and lipid profile is recommended. May increase risk of gallstones and pancreatitis; stop and seek care if severe abdominal pain occurs.

Statins (increased myopathy risk), warfarin/other anticoagulants (may increase bleeding—monitor INR), cyclosporine/tacrolimus (renal risk), bile acid sequestrants like cholestyramine/colestipol (reduced absorption—separate dosing), glitazones such as pioglitazone/rosiglitazone (lipid changes; monitor)

Store at room temperature (below 25°C), protected from moisture and light. Keep in original blister pack and out of reach of children.

Fenofibrate 145 mg tablet (generic), Lipicard 160 Tablet, Fenoglide 120 Tablet, Lofibra 160 Tablet, Fenolip 145 Tablet